Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1980 1
1982 1
1984 3
1988 2
1989 1
1998 1
1999 4
2001 1
2002 1
2005 2
2006 1
2007 1
2008 2
2009 1
2011 3
2012 2
2014 2
2015 3
2016 4
2018 1
2019 3
2020 4
2021 12
2022 11
2023 4
2024 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
Multiple Sclerosis Progression and Relapse Activity in Children.
Iaffaldano P, Portaccio E, Lucisano G, Simone M, Manni A, Guerra T, Paolicelli D, Betti M, De Meo E, Pastò L, Razzolini L, Rocca MA, Ferrè L, Brescia Morra V, Patti F, Zaffaroni M, Gasperini C, De Luca G, Ferraro D, Granella F, Pozzilli C, Romano S, Gallo P, Bergamaschi R, Coniglio MG, Lus G, Vianello M, Banfi P, Lugaresi A, Totaro R, Spitaleri D, Cocco E, Di Palma F, Maimone D, Valentino P, Torri Clerici V, Protti A, Maniscalco GT, Salemi G, Pesci I, Aguglia U, Lepore V, Filippi M, Trojano M, Amato MP; Italian Multiple Sclerosis Register. Iaffaldano P, et al. JAMA Neurol. 2024 Jan 1;81(1):50-58. doi: 10.1001/jamaneurol.2023.4455. JAMA Neurol. 2024. PMID: 38010712
The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.
IST-3 collaborative group; Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, Innes K, Venables G, Czlonkowska A, Kobayashi A, Ricci S, Murray V, Berge E, Slot KB, Hankey GJ, Correia M, Peeters A, Matz K, Lyrer P, Gubitz G, Phillips SJ, Arauz A. IST-3 collaborative group, et al. Lancet. 2012 Jun 23;379(9834):2352-63. doi: 10.1016/S0140-6736(12)60768-5. Epub 2012 May 23. Lancet. 2012. PMID: 22632908 Free PMC article. Clinical Trial.
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.
Perrone F, Piccirillo MC, Ascierto PA, Salvarani C, Parrella R, Marata AM, Popoli P, Ferraris L, Marrocco-Trischitta MM, Ripamonti D, Binda F, Bonfanti P, Squillace N, Castelli F, Muiesan ML, Lichtner M, Calzetti C, Salerno ND, Atripaldi L, Cascella M, Costantini M, Dolci G, Facciolongo NC, Fraganza F, Massari M, Montesarchio V, Mussini C, Negri EA, Botti G, Cardone C, Gargiulo P, Gravina A, Schettino C, Arenare L, Chiodini P, Gallo C; TOCIVID-19 investigators, Italy. Perrone F, et al. J Transl Med. 2021 Oct 21;19(1):442. doi: 10.1186/s12967-021-03094-9. J Transl Med. 2021. PMID: 34674735 Free PMC article. No abstract available.
A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis.
Iaffaldano P, Lucisano G, Guerra T, Paolicelli D, Portaccio E, Inglese M, Foschi M, Patti F, Granella F, Romano S, Cavalla P, De Luca G, Gallo P, Bellantonio P, Gallo A, Montepietra S, Di Sapio A, Vianello M, Quatrale R, Spitaleri D, Clerici R, Torri Clerici V, Cocco E, Brescia Morra V, Marfia GA, Boccia VD, Filippi M, Amato MP, Trojano M; Italian MS Register. Iaffaldano P, et al. Among authors: clerici r. Ann Clin Transl Neurol. 2024 Aug;11(8):2008-2015. doi: 10.1002/acn3.52118. Epub 2024 Jul 5. Ann Clin Transl Neurol. 2024. PMID: 38970214 Free PMC article.
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.
Perrone F, Piccirillo MC, Ascierto PA, Salvarani C, Parrella R, Marata AM, Popoli P, Ferraris L, Marrocco-Trischitta MM, Ripamonti D, Binda F, Bonfanti P, Squillace N, Castelli F, Muiesan ML, Lichtner M, Calzetti C, Salerno ND, Atripaldi L, Cascella M, Costantini M, Dolci G, Facciolongo NC, Fraganza F, Massari M, Montesarchio V, Mussini C, Negri EA, Botti G, Cardone C, Gargiulo P, Gravina A, Schettino C, Arenare L, Chiodini P, Gallo C; TOCIVID-19 investigators, Italy. Perrone F, et al. J Transl Med. 2020 Oct 21;18(1):405. doi: 10.1186/s12967-020-02573-9. J Transl Med. 2020. PMID: 33087150 Free PMC article. Clinical Trial.
A new national survey of centers for cognitive disorders and dementias in Italy.
Bacigalupo I, Giaquinto F, Salvi E, Carnevale G, Vaccaro R, Matascioli F, Remoli G, Vanacore N, Lorenzini P; Permanent Table of the National Dementia Plan Study Group and the CCDDs Study Group. Bacigalupo I, et al. Neurol Sci. 2024 Feb;45(2):525-538. doi: 10.1007/s10072-023-06958-8. Epub 2023 Aug 18. Neurol Sci. 2024. PMID: 37592124 Free PMC article.
Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study.
Chisari CG, Aguglia U, Amato MP, Bergamaschi R, Bertolotto A, Bonavita S, Morra VB, Cavalla P, Cocco E, Conte A, Cottone S, De Luca G, Di Sapio A, Filippi M, Gallo A, Gasperini C, Granella F, Lus G, Maimone D, Maniscalco GT, Marfia G, Moiola L, Paolicelli D, Pesci I, Ragonese P, Rovaris M, Salemi G, Solaro C, Totaro R, Trojano M, Vianello M, Zaffaroni M, Lepore V, Patti F; Italian MS Register Study Group. Chisari CG, et al. Neurotherapeutics. 2024 Jul;21(4):e00363. doi: 10.1016/j.neurot.2024.e00363. Epub 2024 May 7. Neurotherapeutics. 2024. PMID: 38714462 Free PMC article.
Incidence and Long-term Functional Outcome of Neurologic Disorders in Hospitalized Patients With COVID-19 Infected With Pre-Omicron Variants.
Beretta S, Cristillo V, Camera G, Morotti Colleoni C, Pellitteri G, Viti B, Bianchi E, Gipponi S, Grimoldi M, Valente M, Guttmann S, Cotelli MS, Palumbo P, Gelosa G, Meletti S, Schenone C, Ottaviani D, Filippi M, Zini A, Basilico P, Tancredi L, Cortelli P, Braga M, De Giuli V, Servidei S, Paolicelli D, Verde F, Caproni S, Pisani A, Lo Re V, Massacesi L, Roccatagliata DV, Manganotti P, Spitaleri D, Formenti A, Piccioli M, Marino S, Polverino P, Aguglia U, Ornello R, Perego E, Siciliano G, Merlo P, Capobianco M, Pantoni L, Lugaresi A, Angelocola S, De Rosa A, Sessa M, Beghi E, Agostoni EC, Monaco S, Padovani A, Priori A, Silani V, Tedeschi G, Ferrarese C; for Neuro-COVID Italy. Beretta S, et al. Neurology. 2023 Aug 29;101(9):e892-e903. doi: 10.1212/WNL.0000000000207534. Epub 2023 Jul 6. Neurology. 2023. PMID: 37414564 Free PMC article.
Signs and symptoms of COVID-19 in patients with multiple sclerosis.
Schiavetti I, Carmisciano L, Ponzano M, Cordioli C, Cocco E, Marfia GA, Inglese M, Filippi M, Radaelli M, Bergamaschi R, Immovilli P, Capobianco M, De Rossi N, Brichetto G, Scandellari C, Cavalla P, Pesci I, Confalonieri P, Perini P, Trojano M, Lanzillo R, Tedeschi G, Comi G, Battaglia MA, Patti F, Salvetti M, Sormani MP; MuSC-19 Study Group. Schiavetti I, et al. Eur J Neurol. 2022 Dec;29(12):3728-3736. doi: 10.1111/ene.15554. Epub 2022 Sep 23. Eur J Neurol. 2022. PMID: 36086905 Free PMC article.
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis.
Portaccio E, Fonderico M, Iaffaldano P, Pastò L, Razzolini L, Bellinvia A, De Luca G, Ragonese P, Patti F, Brescia Morra V, Cocco E, Sola P, Inglese M, Lus G, Pozzilli C, Maimone D, Lugaresi A, Gazzola P, Comi G, Pesci I, Spitaleri D, Rezzonico M, Vianello M, Avolio C, Logullo FO, Granella F, Salvetti M, Zaffaroni M, Lucisano G, Filippi M, Trojano M, Amato MP; Italian Multiple Sclerosis Register Centers Group. Portaccio E, et al. JAMA Neurol. 2022 Sep 1;79(9):869-878. doi: 10.1001/jamaneurol.2022.1929. JAMA Neurol. 2022. PMID: 35877104 Free PMC article. Clinical Trial.
67 results